Devyser DiagnosticsDVYSR
DVYSR logo
Fair Value
SEK 156.12
Share price17 Dec
SEK 61.860.4% undervalued intrinsic discount
Loading
1Y-52.39%
7D1.81%

Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
17 Dec 25
Views
23
Not Invested

Fair Value vs Share Price

SEK 156.12
vs SEK 61.860.4% undervalued intrinsic discount
PastFuture-61m604m2018202020222024202520262028Revenue SEK 604.0mEarnings SEK 175.1m
35.5%
Revenue growth
29%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Devyser Diagnostics

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with high growth potential.

Market capSEK 1.0b
PB2.9x
Estimated Growth20.6%
Dividend YieldN/A
Full analysis

CEO & management

Jan Wahlstrom
CEO
3.7yrs
CEO Tenure

Provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.